Ivabradine: the evidence of its therapeutic impact in angina
作者： Guillaume Marquis-Gravel , Jean-Claude Tardif
DOI: 10.3355/CE.2008.008
关键词: Cardiology 、 Coronary artery disease 、 Amlodipine 、 Angina 、 Heart rate 、 Heart failure 、 Medicine 、 Ivabradine 、 Beta blocker 、 Atenolol 、 Internal medicine
摘要: Introduction: Stable angina pectoris (SAP) is a widely prevalent disease affecting 30 000 to 40 per million people in Europe and the US. SAP associated with reductions quality of life ability work, increased use healthcare resources. Ivabradine drug unique therapeutic target, If current sinus node, developed for treatment cardiovascular diseases including SAP. It has an exclusive heart rate reducing effect, without any negative effect on left ventricular function or coronary vasodilatation. Aims: The aim this paper review evidence concerning ivabradine Evidence review: effective antianginal antiischemic drug, not inferior beta blocker atenolol calcium channel antagonist (CCA) amlodipine. decreases frequency attacks increases time anginal symptoms during exercise. Because its chronotropic typical adverse reactions blockers other drugs. Clinical value: shows that very good agent, being as blockade CCA therapy controlling myocardial ischemia stable angina. Ongoing studies will determine potential improve morbidity mortality artery failure.
sci-hub.se 参考文章(47)
Michal Tendera, Klinika Kardiologii, I Ford, K Fox, J.c. Tardif, Abstract 3363: Anti-Ischemic and Antianginal Efficacy of Ivabradine, a Selective and Specific If Current Inhibitor, in Elderly Patients with Stable Angina Circulation. ,vol. 114, ,(2006)
Irina Savelieva, A. John Camm, Novel If Current Inhibitor Ivabradine: Safety Considerations Advances in Cardiology. ,vol. 43, pp. 79- 96 ,(2006) , 10.1159/000095430
B Ghaleh, A Berdeaux, L Puybasset, L Simon, J F Giudicelli, Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. Journal of Pharmacology and Experimental Therapeutics. ,vol. 275, pp. 659- 666 ,(1995)
S C Griffin, J A Barber, A Manca, M J Sculpher, S G Thompson, M J Buxton, H Hemingway, Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study BMJ. ,vol. 334, pp. 624- 624 ,(2007) , 10.1136/BMJ.39129.442164.55
Melvin D. Cheitlin, Adolph M. Hutter, Ralph G. Brindis, Peter Ganz, Sanjay Kaul, Richard O. Russell, Randall M. Zusman, James S. Forrester, Pamela S. Douglas, David P. Faxon, John D. Fisher, Raymond J. Gibbons, Jonathan L. Halperin, Adolph M. Hutter, Judith S. Hochman, Sanjiv Kaul, William S. Weintraub, William L. Winters, Michael J. Wolk, Use of sildenafil (Viagra) in patients with cardiovascular disease Journal of the American College of Cardiology. ,vol. 33, pp. 273- 282 ,(1999) , 10.1016/S0735-1097(98)00656-1
Bramah N. Singh, Safety profile of bepridil determined from clinical trials in chronic stable angina in the United States. American Journal of Cardiology. ,vol. 69, pp. 68- 74 ,(1992) , 10.1016/0002-9149(92)90962-X
WILLIAM B. KANNEL, Menopause and Risk of Cardiovascular Disease Annals of Internal Medicine. ,vol. 85, pp. 447- 452 ,(1976) , 10.7326/0003-4819-85-4-447
Matthias Manz, Marcus Reuter, Gerhard Lauck, Hegder Omran, Werner Jung, A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. The Cardiology. ,vol. 100, pp. 149- 155 ,(2003) , 10.1159/000073933
Jeffrey S. Borer, Kim Fox, Patrice Jaillon, Guy Lerebours, Antianginal and Antiischemic Effects of Ivabradine, an If Inhibitor, in Stable Angina Circulation. ,vol. 107, pp. 817- 823 ,(2003) , 10.1161/01.CIR.0000048143.25023.87
S DEPORTU, E MENDITTO, L SCALONE, S BUSTACCHINI, C CRICELLI, L MANTOVANI, The pharmacoeconomic impact of amlodipine use on coronary artery disease. Pharmacological Research. ,vol. 54, pp. 158- 163 ,(2006) , 10.1016/J.PHRS.2006.04.002